Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Elastagen
Sydney, New South Wales, Australia
- Ownership
- Private
- Development stage
- Other
01
Overview
Elastagen developed a proprietary platform using recombinant human tropoelastin—a biomaterial identical to the natural precursor of elastin—to create injectable products for aesthetic medicine and tissue/wound repair. The company demonstrated safety and efficacy in multiple clinical studies targeting acne scars, stretch marks, burns, chronic wounds, and general aesthetic improvement. Its technology was considered highly innovative within regenerative medicine. In early 2018 it was acquired by Allergan for an upfront payment of $95 million plus contingent payments; total deal value reported as over $350 million. This was one of the largest healthcare exits in Australian biotech history.
- Therapeutic areas
- Dermatology
- Modalities
- Recombinant proteins (specifically recombinant human tropoelastin)
- Industry
- Implantable Medical Devices
02
Partnerships
University of Sydney (founding academic partner/licensor)Cicada Innovations incubator support during early growth phase
Beyond the preview
Go deeper on Elastagen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elastagen.